Rezolute Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

Company Overview - Rezolute, Inc. is a late-stage biopharmaceutical company focused on developing therapies for rare diseases, particularly those with serious unmet needs [2] - The company is dedicated to improving outcomes for individuals suffering from hypoglycemia caused by hyperinsulinism (HI) [2] Recent Developments - The compensation committee of Rezolute has approved the issuance of 150,000 shares of common stock as an inducement award to its new Senior Vice President of Global Product Supply [1] - This inducement award was granted on November 30, 2024, and priced at the closing price on November 29, 2024 [1] - The award will vest 25% one year after the executive's start date and will vest monthly for the following 36 months [1] Product Information - Rezolute's primary product, ersodetug, is an antibody therapy designed to treat all forms of hyperinsulinism and has demonstrated substantial benefits in clinical trials and real-world applications for congenital and tumor HI [2]